Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA) - PREVENT-JIA

Westfaelische Wilhelm Universitaet0 个研究点目标入组 33 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patients with polyarticular course of any JIA subcategory (including extended oligoarthritis
•and polyarticular course of systemic JIA without systemic features) will be included at first
•confirmation of remission on medication, i.e. after clinically documented inactive disease (no
•joints with active arthritis; no fever, rash, serositis, splenomegaly, or generalized
•lymphadenopathy attributable to JIA; no active uveitis; no elevation in ESR or/and CRP
•attributable to JIA; physician*s global assessment of disease activity indicates no disease
•activity) for at least 6 months. Alternatively patients can be enrolled until 12 months (+/- 6
•weeks) to ensure access to the study after 6 months of inactive disease. At the time
•remission is documented, patients may be ONLY on non-steroidal anti-inflammatory drugs
•(NSAIDs) plus DMARDs and/or biologics at a stable dose. Only approved medication is
•allowed during the study. Steroids must have been withdrawn at least 1 month before
•remission is documented. Intraarticular joint injections should not have been performed 6
•months before remission is documented. At inclusion into this study patients will be
•considered being in clinically documented remission on medication.

•Patients with persistent oligoarthritis subtype or systemic JIA having systemic features
•(within 1 year prior to inclusion) are excluded.
•In addition, patients may not have received treatment with steroids in the month before remission is first documented or treatment with intraarticular joint injections etc. in the 6 months before remission is first documented.
•Patient with a history of uveitis or macrophage activation syndrome are excluded.
•Patients may also not be included if withdrawal of any biological drug has ever been unsuccessful in the past.
•Patients who are not followed for pharmacovigilance in our anonymized Pharmachild-database.

发起方

Westfaelische Wilhelm Universitaet